News

Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

A case series illuminates neuro-ophthalmologic manifestations, retinal vascular involvement and other pathologies

Depending on results from the survey for healthcare professionals, a scope expansion for eIFUs could impact ophthalmic devices including contact lenses.

The PPQ campaign consisted of the production of 3 successful consecutive commercial-scale drug substance batches required for the validation of Opthea’s manufacturing process.

Oral gildeuretinol demonstrated a clinically meaningful reduction in the GA lesion growth rate at 24 months in the SAGA study.

Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has been accepted as a late breaker at the 128th annual meeting of the American Academy of Ophthalmology, being held October 18-21 in Chicago.

Cutting-edge approaches for MDs and ODs

The research team used spectral-domain OCT and OCT angiography imaging to study the changes in the retinal microvasculature in patients

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement.

Dr Margaret A. Chang shares data on the port delivery system with ranibizumab, and her strategy for making the most of conferences

The new standard: Stabilizing keratoconus and improving vision.

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

Opthea Limited has made changes to the company’s executive leadership in its and notable hires in senior roles.

IVW-1001 is a novel TRPM8 agonist delivered via ophthalmic eyelid wipe, being developed to treat DED.

Unlocking the potential of donor scleral tissue: Innovations and future applications.

The report urges the US Department of Health and Human Services, in collaboration with departments of education at the state level, to take measures to ensure that children receive a vision screening before first grade and a comprehensive eye exam, when needed.

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, being held October 18 to 21 in Chicago, Illinois.

Gene therapy offers a promising alternative by potentially providing long-lasting effects from a single treatment.

The announcement marks the second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation.

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology.

Option provides surgeons with flexibility and creativity.

Retina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting.

German researchers found that their study results suggest that the effect of glaucoma on the elapsed time depends on disease progression. This uncertainty during everyday navigation tasks may adversely affect patients’ quality of life.

Prevent Blindness is offering free resources to help educate the public and allied healthcare professionals on the many types of inflammatory eye diseases, and steps that should be taken to prevent vision loss.